Brammer Bio

18 articles about Brammer Bio

• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
• 

  Amicus Inks Deal with Thermo Fisher’s Brammer Bio

  7/1/2019

  Under the agreement, Thermo Fisher will provide Amicus with immediate clinical and commercial manufacturing capabilities and capacity for Amicus’ intrathecal AAV Batten disease gene therapy programs.

• Thermo Fisher Scientific Completes Acquisition of Brammer Bio

  5/1/2019

  Thermo Fisher Scientific Inc. announced that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.

• Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

  4/2/2019

  Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies

• Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing

  3/25/2019

  Significantly expands capabilities to support high-growth gene and cell therapy market

• 

  Thermo Fisher Scientific to Buy Brammer Bio for $1.7 Billion

  3/25/2019

  Brammer has about 600 staffers at its primary locations in Massachusetts and Florida. The company was projected to bring in $250 million in revenue this year.

• Brammer Bio Supports Rare Disease Day

  2/28/2019

  Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.

• Brammer Bolsters Leadership Team and Announces Chief Quality Officer

  1/3/2019

  Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the growth of the organization.

• Brammer Bio is Named Manufacturing Company of the Year

  11/28/2018

  Brammer Bio ("Brammer"), a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO), was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program.

• Brammer Bio announces progress on $200 million program to advance gene therapies

  9/26/2018

  Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

• Brammer Bio Expands Leadership Team for Commercial Readiness

  3/20/2018

  Brammer Bio announces recent leadership appointments to support the growth of the organization.

• Brammer Bio Launches Gene Therapy Product Manufacturing Operations in MA

  11/27/2017

  The facility houses state-of-the-art equipment in cleanroom suites specially designed to accommodate a broad-range of gene therapy manufacturing process technologies.

• Abeona Therapeutics And Brammer Bio Announce Collaboration For Commercial Translation Of ABO-102

  9/28/2017

• Brammer Bio Expands Cell And Gene Therapy Capacity In Florida And Massachusetts, Partnering With Pall Life Sciences For Suspension And Adherent Platform Technologies

  9/25/2017

• Brammer Bio Completes Expansion Of Cell And Gene Therapy Clinical Manufacturing Facilities In Florida

  9/18/2017

• Brammer Bio Appoints Leading Commercial Manufacturing And Gene Therapy Expert As Chief Manufacturing Officer

  6/20/2017

• Lysogene Selects Brammer Bio To Produce GM1 Gangliosidosis Gene Therapy Product

  5/24/2017

• Brammer Bio Announces Major Milestone In Establishing Commercial-Ready Gene Therapy Supply For The Industry

  5/9/2017